Research programme: therapeutic cancer vaccines - Vakzine Project Management
Alternative Names: MEL-131 IL-2/IFNγ; SK-RC-28 IL-2/IFNγLatest Information Update: 16 Jul 2016
Price :
$50 *
At a glance
- Originator Vakzine Projekt Management
- Class
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Malignant melanoma; Renal cancer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Malignant-melanoma in Germany
- 16 Jul 2016 No recent reports of development identified for preclinical development in Renal-cancer in Germany
- 12 Dec 2005 Preclinical trials in Malignant melanoma in Germany (unspecified route)